General
Preferred name
BEZITRAMIDE
Synonyms
N02AC05 ()
R 4845 ()
Bezitramida ()
IDS-NB-007 ()
R-4845 ()
Burgodin ()
P&D ID
PD008853
CAS
15301-48-1
Tags
available
drug
Drug Status
withdrawn
approved
investigational
illicit
Max Phase
2.0
Drug indication
Pain
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
A narcotic analgesic once used for the treatment of severe chronic pain. [A14383]
PHARMACODYNAMICS
Bezitramide acts in the body to relieve pain with a potency 20 times that of methadone [A14383]. Its duration of action is relatively long, lasting up to 12 hours post oral administration, after the achievement of steady state. Its onset of action is slow, with a peak in analgesic effect noted between 2.5-3.5 hours after dosing. It is noted to illicit a strong antitussive effect, which could be of benefit to patients with bronchial carcinoma.
ROE
Less than 0.3% of the dose was excreted unchanged in the urine. High concentrations in feces suggested incomplete absorption of biliary excretion. Experiments in rats demonstrated extensive (up to 70%) biliary excretion, and less than 3% urinary excretion. [A14383]
METABOLISM
Bezitramide is a prodrug which undergoes rapid hydrolysis of a proprionyl-group to form the major metabolite, R-4618. R-4618 has analgesic properties similar to the parent compound.[A14383] Metabolism occurs in the gastrointestinal tract under both acidic and alkaline conditions [A14383].
ABSORPTION
Bezitramide has poor water solubility, thus administration is restricted to the oral route. [A14383]
ROE
Less than 0.3% of the dose was excreted unchanged in the urine. High concentrations in feces suggested incomplete absorption of biliary excretion.; ; Experiments in rats demonstrated extensive (up to 70%) biliary excretion, and less than 3% urinary excretion. [A14383] ;
HALF-LIFE
11-24h. [A14383]
PHARMACODYNAMICS
Bezitramide acts in the body to relieve pain with a potency 20 times that of methadone [A14383]. Its duration of action is relatively long, lasting up to 12 hours post oral administration, after the achievement of steady state. Its onset of action is slow, with a peak in analgesic effect noted between 2.5-3.5 hours after dosing. ; ; It is noted to illicit a strong antitussive effect, which could be of benefit to patients with bronchial carcinoma. ; ; ;
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
8
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
23
Molecular Weight
492.25
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
5.39
TPSA
71.03
Fraction CSP3
0.32
Chiral centers
0.0
Largest ring
6.0
QED
0.35
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
ATC
N02AC05
Source data

